Advertisement
PCVX vs REGN
Which Stock Would AI Choose? Vaxcyte (PCVX) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- PCVX (Vaxcyte) is a clinical-stage vaccine developer whose lead candidate, VAX-31, recently reported positive late-stage trial results, triggering a sharp rally in the shares.
- REGN (Regeneron Pharmaceuticals) is a profitable, commercial-stage biopharmaceutical company with diversified revenue from Dupixent, Eylea HD, and Libtayo.
- The two stocks represent fundamentally different risk profiles: pre-revenue, catalyst-driven development versus established, cash-generating scale.
- PCVX offers higher potential upside tied to binary clinical and regulatory outcomes, while REGN offers steadier earnings, a dividend, and share buybacks.
- Both companies compete within the pneumococcal vaccine market, but from opposite positions: Vaxcyte as a challenger and Regeneron only indirectly through its broader immunology and ophthalmology focus.
Introduction
Investors evaluating the biotechnology sector often face a choice between high-upside, pre-commercial innovators and diversified, profitable industry leaders. This stock comparison examines two such companies: PCVX (Vaxcyte, Inc.), a clinical-stage vaccine maker with a single lead program driving its valuation, and REGN (Regeneron Pharmaceuticals, Inc.), a large-cap biopharmaceutical firm with multiple marketed blockbusters. Growth-oriented traders may find PCVX's catalyst-driven price action compelling, while investors seeking cash flow, dividends, and lower volatility may gravitate toward REGN. Understanding their relative performance and market positioning can help clarify which profile better suits a given portfolio.
PCVX Overview and Recent Performance
Vaxcyte is a vaccine innovation company focused on engineering high-fidelity vaccines against bacterial diseases. Its flagship candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) — a vaccine designed to protect against the bacterium Streptococcus pneumoniae — and is considered the broadest-spectrum PCV candidate in clinical development. In recent weeks, PCVX announced that VAX-31 met the primary goals of its OPUS-1 Phase 3 pivotal adult trial, a milestone that drove a dramatic surge in the stock as investors repriced the program's commercial prospects.
This positive catalyst reversed a period of consolidation in the shares. Vaxcyte remains pre-revenue, funding its pipeline through a cash position of approximately $2.5 billion reported as of mid-2026, and it continues to post net losses as research and development (R&D) spending expands alongside its Phase 3 and manufacturing buildout. Sentiment has been shaped largely by the VAX-31 data readout, with analysts raising price targets in its wake.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals is a commercial-stage biopharmaceutical company with a diversified portfolio spanning immunology, ophthalmology, and oncology. Its key growth drivers include Dupixent, a blockbuster medicine for type 2 inflammatory diseases marketed with Sanofi; Eylea HD, a high-dose treatment for retinal diseases; and Libtayo, a cancer immunotherapy. In recent quarters, REGN reported double-digit revenue and earnings growth, with each of these three products reaching record quarterly sales, while Dupixent has been annualizing at roughly $24 billion in global sales.
Regeneron has also repaid its Sanofi development balance, a step expected to lift collaboration profits, and it has returned capital to shareholders through buybacks and a recently initiated dividend. The stock has traded near its 52-week high in recent weeks, reflecting steady execution and a deep pipeline, though it faces ongoing biosimilar competition in the lower-dose Eylea segment.
Trending AI Robots
For traders who prefer a data-driven approach to comparing opportunities like PCVX and REGN, Tickeron offers a curated Trending AI Robots section. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, yet only those best suited to current market conditions earn a place in this focused selection. These bots vary widely in trading style, strategy, timeframe, performance, and the set of tickers they monitor, giving users access to a broad spectrum of automated approaches. The curated list highlights the strongest performers and the most relevant strategies for today's market environment. Explore the Trending AI Robots page to review the latest selections and identify bots aligned with your trading objectives.
Head-to-Head Comparison
The most striking contrast between PCVX and REGN lies in their business models. Vaxcyte is a single-asset, pre-revenue company whose valuation hinges on clinical and regulatory outcomes for VAX-31. Its growth drivers are concentrated and binary: a successful approval could unlock a multi-billion-dollar market, while a setback would concentrate risk sharply. Regeneron, by contrast, generates billions in annual revenue across multiple approved products and more than 50 pipeline programs, diversifying both its earnings base and its risk.
Recent momentum also differs. PCVX has exhibited sharp, event-driven volatility around the VAX-31 readout, whereas REGN has advanced more steadily on consistent commercial execution. Sector exposure varies as well: Vaxcyte competes directly in the pneumococcal vaccine space against large players such as Pfizer and Merck, while Regeneron's exposure to that market is only indirect. On risk factors, Vaxcyte faces regulatory uncertainty and ongoing cash burn, while Regeneron faces patent expirations, biosimilar competition, and payer pricing pressures. In terms of market sentiment, PCVX currently carries an optimistic, catalyst-driven bias, while REGN is viewed as a stable, undervalued large-cap by some analysts.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalysts, Tickeron's AI would likely assess these two stocks differently. For PCVX, the recent Phase 3 success represents a powerful positive catalyst, but the price action has been sharply volatile and the fundamental base remains pre-revenue, making sustained trend consistency harder to confirm. For REGN, steadier price behavior, consistent earnings growth, and a diversified commercial base provide a more stable trend profile. The AI would likely favor REGN on stability and trend consistency, while recognizing that PCVX may offer a stronger short-term momentum signal for risk-tolerant traders. As always, such a verdict is probabilistic and reflects current positioning rather than a guaranteed outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCVX is a Hold and REGN is a Buy.
PCVX in downward trend: price may drop because broke its higher Bollinger Band on October 05, 2026
PCVX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 44 similar instances where the stock broke above the upper band. In 41 of the 44 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PCVX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 30 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PCVX as a result. In 58 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for PCVX turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 35 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for PCVX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
PCVX moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
Following a +4.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 225 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.412) is normal, around the industry mean (2.988). P/E Ratio (-8.287) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
REGN in +5.74% Uptrend, rising for three consecutive days on October 15, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where REGN advanced for three days, in 207 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REGN's RSI Oscillator exited the oversold zone, 17 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 59 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 31 of 49 cases over the following month. The odds of a continued upward trend are 63%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for REGN crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 43%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
REGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.616) is normal, around the industry mean (2.988). P/E Ratio (19.242) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.005) settles around the average of (123.903) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (438.009).
PCVX | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 86 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 72 | 83 | |
SMR RATING 1..100 | 96 | 59 | |
PRICE GROWTH RATING 1..100 | 38 | 18 | |
P/E GROWTH RATING 1..100 | 58 | 15 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCVX's Valuation (20) in the null industry is significantly better than the same rating for REGN (88) in the Biotechnology industry. This means that PCVX’s stock grew significantly faster than REGN’s over the last 12 months.
PCVX's Profit vs Risk Rating (72) in the null industry is in the same range as REGN (83) in the Biotechnology industry. This means that PCVX’s stock grew similarly to REGN’s over the last 12 months.
REGN's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for PCVX (96) in the null industry. This means that REGN’s stock grew somewhat faster than PCVX’s over the last 12 months.
REGN's Price Growth Rating (18) in the Biotechnology industry is in the same range as PCVX (38) in the null industry. This means that REGN’s stock grew similarly to PCVX’s over the last 12 months.
REGN's P/E Growth Rating (15) in the Biotechnology industry is somewhat better than the same rating for PCVX (58) in the null industry. This means that REGN’s stock grew somewhat faster than PCVX’s over the last 12 months.
| PCVX | REGN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 63% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 65% |
| Advances ODDS (%) | 3 days ago 79% | 8 days ago 65% |
| Declines ODDS (%) | 7 days ago 71% | 4 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 51% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PCVX’s FA Score shows that 1 FA rating(s) are green while REGN’s FA Score has 2 green FA rating(s).
- PCVX’s FA Score: 1 green, 4 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PCVX’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 5 bullish TA indicator(s).
- PCVX’s TA Score: 4 bullish, 6 bearish.
- REGN’s TA Score: 5 bullish, 5 bearish.
Price Growth
PCVX (@Biotechnology) experienced а -6.40% price change this week, while REGN (@Biotechnology) price change was +3.51% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.55%. For the same industry, the average monthly price growth was -17.70%, and the average quarterly price growth was -14.66%.
Reported Earning Dates
PCVX is expected to report earnings on Nov 03, 2026.
REGN is expected to report earnings on Oct 30, 2026.
Industries' Descriptions
@Biotechnology (-0.55% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement